Skip to main content

Table 3 The association between oral anticoagulation and outcomes, stratified by frailty category

From: Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial

Unadjusted hazard ratio (95% confidence interval) compared to warfarin (ref), within each frailty category
Fit Pre-frail Mild-moderate frailty Severe frailty
Edoxaban 30 mg Edoxaban 60 mg Edoxaban 30 mg Edoxaban 60 mg Edoxaban 30 mg Edoxaban 60 mg Edoxaban 30 mg Edoxaban 60 mg
Primary endpoints
 Time to first adjudicated stroke or systemic embolism
  1.04 (0.71–1.50) 1.03 (0.71–1.49) 1.18 (0.97–1.43) 0.82 (0.66–1.01) 1.17 (0.87–1.56) 0.84 (0.61–1.15) 0.30 (0.08–1.11) 0.54 (0.20–1.50)
 Time to adjudicated major bleeding during treatment
  0.42 (0.28–0.62) 0.96 (0.71–1.30) 0.46 (0.38–0.56) 0.76 (0.64–0.90) 0.47 (0.35–0.64) 0.75 (0.57–0.98) 0.74 (0.36–1.52) 0.60 (0.29–1.26)
Composite net clinical endpoints
 1. Stroke, systemic embolic event, major bleeding, or death
  0.90 (0.74–1.10) 1.11 (0.92–1.34) 0.83 (0.75–0.92) 0.84 (0.76–0.93) 0.81 (0.70–0.93) 0.90 (0.78–1.03) 0.82 (0.54–1.23) 0.75 (0.50–1.12)
 2. Disabling stroke, life-threatening bleeding, or death
  1.01 (0.79–1.30) 1.11 (0.87–1.41) 0.83 (0.74–0.95) 0.86 (0.76–0.97) 0.79 (0.66–0.94) 0.88 (0.74–1.04) 0.66 (0.41–1.07) 0.62 (0.39–0.99)
 3. Stroke, systemic embolic event, life-threatening bleeding, or death
  1.03 (0.82–1.30) 1.14 (0.91–1.42) 0.89 (0.79–1.00) 0.83 (0.74–0.93) 0.85 (0.72–1.00) 0.88 (0.75–1.04) 0.64 (0.40–1.02) 0.66 (0.42–1.03)
Death
 1.08 (0.83–1.42) 1.20 (0.92–1.56) 0.89 (0.78–1.02) 0.88 (0.77–1.01) 0.83 (0.69–1.00) 0.89 (0.75–1.07) 0.67 (0.41–1.12) 0.69 (0.43–1.12)